Although it is a laudatory objective to publish only articles by authors who have no financial
relationship with corporations or the products and issues discussed in the articles, as …

Although it is a laudatory objective to publish only articles by authors who have no financial
relationship with corporations or the products and issues discussed in the articles, as …

Although it is a laudatory objective to publish only articles by authors who have no financial
relationship with corporations or the products and issues discussed in the articles, as …

The current interest of the public and politicians in the United States over ethics in science
and medicine is not new. Deliberate misrepresentation in science and medicine has always …

Well-known and respected drug companies pay billions in fines for breaking the rules. A Key
opinion leaders crisscross the globe, touting the latest drug or device with inadequate …

We have read with great interest the article by Packer et al. and would like to offer critical
commentary on the use and analysis of StableVisc OVD (Bausch & Lomb, Inc.). 1 We hope …

The editorial regarding conflict of interest 1 provides an important reminder of the ethical
concerns and responsibilities of clinical investigators. While institutions may set varying …

As a clinical pharmacologist (GDN) and bio-statistician (RSC) involved in the design,
analysis, and reporting of hundreds of controlled clinical trials, we found the 2 editorials on …

Collaboration between physicians and companies that invest resources to bring new drugs
and devices into the market has produced great strides in innovation and advances in …

consider the question of when it is appropriate to call for prospective and/or randomized
clinical trials methodology early on in the development of diagnostic or therapeutic …